Kevin Mandia's new security startup Armadin raises $255.5 million with a valuation of $2.5 billion
TechCrunch
49m ago
Ai Focus
The cybersecurity startup Armadin, founded by Kevin Mandia, announced the completion of a $255.5 million Series B financing round, with a valuation exceeding $2.5 billion. This round was led by Andreessen Horowitz and Accel. Just six months after its $190 million Series A financing in March, the company has now raised a total of over $445 million in funding.
Helpful
No.Help

Famous for founding the cybersecurity startup Mandiant, which was sold to Google for $5.4 billion in 2022, Kevin Mandia has now raised $255.5 million for his latest venture, Armadin. The company announced on Thursday that this round of financing has valued Armadin at over $2.5 billion.

This round of Series B financing was led by Andreessen Horowitz and Accel, with participation from Bain Capital Ventures, Redpoint, 8VC, Ballistic Ventures, Google Ventures, In-Q-Tel, Kleiner Perkins, and Menlo Ventures.

It has only been six months since Armadin completed a $190 million Series A financing in March, and now this new round of financing has taken place. To date, the company has raised a total of over $445 million.

Armadin is providing enterprises with a new, round-the-clock security protection approach, reimagining the defense testing of the AI era. Unlike traditional penetration testing, where hired security professionals attempt to infiltrate and report discovered vulnerabilities, Armadin operates a continuous, online agentic. These swarms methods link multiple vulnerabilities to carry out an attack. The idea is to help organizations detect and block vulnerabilities before any mischievous individuals, or even those in AI laboratories with uncontrolled agents, can launch attacks using agentic technology.

Tip
$0
Like
0
Save
0
Views 13
CoinMeta reminds readers to view blockchain rationally, stay aware of risks, and beware of virtual token issuance and speculation. All content on this site represents market information or related viewpoints only and does not constitute any form of investment advice. If you find sensitive content, please click“Report”,and we will handle it promptly。
Submit
Comment 0
Hot
Latest
No comments yet. Be the first!
Related
Vylor has been included in the S&P 500; Twilio will join the S&P 500; other companies will enter the S&P MidCap 400 and S&P SmallCap 600
S&P Dow Jones Indices announces adjustments to the S&P 500, S&P 400, and S&P 600. Vylor will be included in the S&P 500 due to the Corteva spin-off, and Twilio will replace Warner Bros. Discovery will enter the S&P 500, with these changes taking effect before the opening on October 6th.
PR Newswire
·2026-10-02 06:44:01
12
Lyft Reaches $272.5 Million Settlement in Driver Classification Litigation
Lyft agrees to pay $272.5 million to settle a lawsuit accusing it of incorrectly classifying drivers as independent contractors rather than employees. The company says this settlement will help avoid the costs and disruptions associated with lengthy litigation; however, the settlement is still subject to approval by a judge.
TechCrunch
·2026-10-02 06:18:35
13
SEC or investors who are allowed to pass the exam may enter the private equity market. The rules might look something like this.
The U.S. Securities and Exchange Commission announced a package of proposed rules and regulatory actions on Wednesday, aiming to make it easier for more people to invest in private equity, private credit, and other private market funds. One of the proposals is to add a new pathway to become a "qualified investor" by passing an exam. This exam will be designed by the U.S. Financial Regulatory Agency FINRA and will be open to individuals 18 years of age and older. The cost is expected to be similar to that of the existing SIE exam.
Businessinsider
·2026-10-02 06:18:33
11
Axogen Completes Acquisition of BioCircuit Technologies, Adding the First Seamless Peripheral Nerve Repair Device NerveTape Approved by FDA
Axogen announces the completion of its acquisition of BioCircuit Technologies, whose developed NerveTape is the first sutureless peripheral nerve repair device to be approved by FDA. The company expects BioCircuit to contribute approximately $6 million in revenue in the fourth quarter of 2026 and about $34 million in revenue in 2027.
GlobeNewswire
·2026-10-02 05:56:20
19
View More